???? C??? ??, ??, ??

??

Pertuzumab is an anti-human epidermal growth factor receptor 2 (HER2) antibody that was approved by the US FDA in June 2012 for use in combination with trastuzumab (Herceptin) and docetaxel chemotherapy for the treatment of people with HER2-positive (HER2⁺) metastatic breast cancer (mBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Pertuzumab inhibits HER2 dimer formation with other HER members, such as HER1 and HER3, thus inhibiting the downstream signaling processes associated with tumor growth and progression. Pertuzumab is the first HER2 dimerization inhibitor to reach the market. The mechanism of actions of trastuzumab and pertuzumab are believed to complement each other and provide a more comprehensive inhibition of tumor growth than either agent alone. Preclinical data showed that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in xenograft models, something that cannot be achieved by either monotherapy alone.

??

Anti-neoplastic.

???? ?? ?? ? ???

???

?? ??

???? ?? ??

???	??	???	??	?? ?	??
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	965	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19936	58
TopScience Biochemical	00852-68527855	info@itopbiochem.com	China Hong Kong	902	58
career henan chemical co	+86-0371-86658258 +8613203830695	factory@coreychem.com	China	29792	58
Shanghai Minbiotech Co., Ltd.	+8617315815539	sales@minbiotech.com	CHINA	129	58
Baoji Guokang Healthchem co.,ltd	+8615604608665 15604608665	dominicguo@gk-bio.com	CHINA	9414	58
Hefei Hirisun Pharmatech Co., Ltd	+8615056975894	shawn@hirisunpharm.com	CHINA	9911	58
Hangzhou Huarong Pharm Co., Ltd.	571-86758373 +8613588754946	sales@huarongpharm.com	CHINA	3148	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6391	58
TargetMol Chemicals Inc.	+1-781-999-5354;	support@targetmol.com	United States	39037	58

???? ?? ??: